What is Geron's cash and cash equivalents, end of period?

Geron (GERN) reported cash and cash equivalents, end of period of $70.78M in Q1 2026.

How has Geron's cash and cash equivalents, end of period changed year-over-year?

Geron's cash and cash equivalents, end of period decreased by 17.3% year-over-year, from $85.61M to $70.78M.

What is the long-term trend for Geron's cash and cash equivalents, end of period?

Over 2 years (2023 to 2025), Geron's cash and cash equivalents, end of period has grown at a 5.7% compound annual growth rate (CAGR), from $71.14M to $79.44M.

Geron GERN Cash and cash equivalents, end of period

Cash and cash equivalents, end of period at other companies

Arcus BiosciencesRCUS

——

CelcuityCELC

——

Tango TherapeuticsTNGX

——

Eli LillyLLY

——

Other financials

Income statement

See full

Revenue$51.8M+30.9%

Operating income$158.0K+101%

Net income-$3.6M+81.6%

EPS (diluted)-$0.01+66.7%

Balance sheet

See full

Cash & equivalents$48.7M-12.2%

Total debt$134.0M+10.0%

Total equity$229.1M-14.6%

Total assets$534.1M-5.0%

Cash flow

See full

Operating cash flow-$62.9M-31.1%

CapEx$206.0K+2.0%

Free cash flow-$43.8M-6.8%

Valuation

See full

Market cap$878.88M-8.6%

Enterprise value$964.15M-6.2%

P/S4.7×-172×

Profitability

See full

Operating margin-705.5%-351pp

Net margin-682.5%-339pp

FCF margin-734.4%-365pp

Returns & leverage

See full

Return on equity-27.1%-7.8pp

Debt / equity0.6×+0.1×

Current ratio6.8×-1.1×

Where this comes from

Reported directly by Geron in its filing.

Tagged under the XBRL concept us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations.

The official record: Geron’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Geron's cash and cash equivalents, end of period.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Geron's cash and cash equivalents, end of period?: Geron (GERN) reported cash and cash equivalents, end of period of $70.78M in Q1 2026.
How has Geron's cash and cash equivalents, end of period changed year-over-year?: Geron's cash and cash equivalents, end of period decreased by 17.3% year-over-year, from $85.61M to $70.78M.
What is the long-term trend for Geron's cash and cash equivalents, end of period?: Over 2 years (2023 to 2025), Geron's cash and cash equivalents, end of period has grown at a 5.7% compound annual growth rate (CAGR), from $71.14M to $79.44M.